Mark Robbins, Ph.D., J.D., is a Senior Advisor with Intensity and an expert in the pharmaceutical and biotechnology industry. Dr. Robbins has more than 35 years of experience in consulting, teaching, and drug/medical device research and commercialization, which he applies in providing expert services in pharmaceutical antitrust and patent litigation. Dr. Robbins has provided expert testimony in a number of high-profile cases that included:
- “Product hopping” pharmaceutical antitrust litigation on a generic birth control medication
- Alleged unfair competition related to compounded drugs that violated the Lanham Act
- Alleged unfair competition in violation of California’s Sherman Food, Drug and Cosmetic Law related to compounded drugs
- Pharmaceutical antitrust litigation alleging pharmaceutical monopolistic behavior by “pay for delay”
- Biotechnology patent infringement case for a breast cancer treatment
- Pharmaceutical antitrust case based on an alleged anticompetitive exclusive licensing agreement.
- End-payor purchases contended anticompetitive practices caused them to pay an overcharge
Dr. Robbins has served as an Adjunct Assistant Professor at the University of Minnesota College of Pharmacy and an Adjunct Professor (Food and Drug Law) at the William Mitchell College of Law. He is a frequent guest lecturer at professional seminars such as the Food and Drug Law Institute Annual meeting, and has written articles in a number of notable publications including:
- Pharmacology Biochemistry and Behavior
- Biochemical Pharmacology
- The Journal of Nuclear Medicine
- Life Sciences
- Investigative Radiology
- The Journal of Medicinal Chemistry
- Seminars in Nuclear Medicine
In addition to his work with Intensity, Dr. Robbins is the CEO and President of Kodiak Strategic Consultants. He previously served as CEO and President at a therapeutics firm, COO at a biotechnology firm, and has held various roles with pharmaceutical firms.
Dr. Robbins earned a B.S. degree in Biochemistry from the University of California at Los Angeles, a Ph.D., in Pharmacology from the University of Minnesota Medical School, and a J.D. from the St. Louis University School of Law.